Synthetic Biology at Scale: Less Disruption, More Cohesion
![](https://antheia.bio/wp-content/uploads/2023/07/Industrial-Fermentation-2-2-1024x683.webp)
For synthetic biology companies, scaling up means reaching out—working with government bodies, identifying partners, and securing manufacturing capacity
Antheia Secures $17 Million to Boost U.S. Production of Critical Pharmaceutical Ingredients
![](https://antheia.bio/wp-content/uploads/2024/07/Christina-Smolke-at-SynBioBeta2023-1.png)
Antheia, a pioneering pharmaceutical ingredient manufacturer, has announced a significant $17 million funding boost aimed at transforming the supply chains of essential medicines.
Antheia Announces $17 Million in Funding for Domestic Pharmaceutical Ingredient Production
![](https://antheia.bio/wp-content/uploads/2024/07/vladimir-solomianyi-rKPiuXLq29A-unsplash-1.png)
Antheia announced that it has received $17 million in funding to be used for projects focused on building domestic pharmaceutical production sites.
Antheia secures new funding to boost pharmaceutical ingredients production
![](https://antheia.bio/wp-content/uploads/2024/07/james-coleman-IMe6fLWEu6E-unsplash-1.png)
The company secured funding through government project agreement with the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), alongside strategic investment from In-Q-Tel and Echo
Secretary of State Antony Blinken visits the Bay Area
![SOS-visit](https://antheia.bio/wp-content/uploads/2024/05/SOS-visit-thumbnail.png)
Antony Blinken tours Antheia biotech lab, emphasizing its potential to address nationwide medicine shortages by overcoming supply chain issues with advanced bio-technology
Chemicals Knowledge Hub: DCAT Week 2024 Andrea Conforto, VP/Biotech for CDMO at Olon and Zack McGahey, COO at Antheia
![Antheia-x-Olon](https://antheia.bio/wp-content/uploads/2024/05/Antheia-x-Olon-thumbnail.png)
In this interview with Antheia and Olon, two leading companies in the life sciences industry, we discussed their ongoing partnership, market trends, and the future of the industry.
PharmaSource: Antheia and Olon Extend Biomanufacturing Partnership
![Olon-partnership](https://antheia.bio/wp-content/uploads/2024/05/Olon-partnership-thumbnail.png)
Antheia and Olon have announced a continuation of partnership, leveraging Olon’s fermentation infrastructure for the manufacture of Antheia’s early products
Antheia and Olon Continue Partnership for Biomanufacturing Antheia’s Pipeline of KSMs and APIs for Essential Medicines
![Press-Release-Thumbnail](https://antheia.bio/wp-content/uploads/2024/01/Press-Release-Thumbnail_Compressed-1024x768.webp)
Antheia and Olon established this partnership in 2022 to leverage Olon’s fermentation sites across Italy. Olon has since played a pivotal role as a CDMO for scaling Antheia’s biomanufacturing processes and producing its Biosynthetic KSMs (key starting materials) and APIs.
Antheia Achieves Major Commercial Milestone
![Press-Release-Thumbnail](https://antheia.bio/wp-content/uploads/2024/01/Press-Release-Thumbnail_Compressed-1024x768.webp)
Company’s first full-scale fermentation run reinforces commercial viability for a robust pipeline of Biosynthetic KSMS and APIs
Introducing Antheia’s Reinvigorated Brand Identity
![](https://antheia.bio/wp-content/uploads/2023/06/Antheia-Menlo-Park-HQ-jpg.webp)
Since launching Antheia in 2015, we’ve made tremendous strides toward our mission to transform pharmaceutical supply chains for essential medicines. We’ve strengthened our leadership team with veteran executives across R&D, operations, supply chain, and quality and regulatory, we’ve repeatedly validated our technology at commercially-relevant scales, and we are now actively moving into full-scale production to bring our products to market.